课件：解读2007NKF-KDOQI指南诠释糖尿病肾病综合防治.pptVIP

* * * 这是一项多中心、随机双盲、安慰剂对照研究，共567名平均年龄54岁的轻中度高血压患者，经药物洗脱期后，随机接受安慰剂、安博维300mg/天、安博维150mg/天或氯沙坦100mg/天，治疗8周。 可以看出，安博维降压效果显著优于氯沙坦。 * 这是一项多中心、随机双盲、安慰剂对照研究，共567名平均年龄54岁的轻中度高血压患者，经药物洗脱期后，随机接受安慰剂、安博维300mg/天、安博维150mg/天或氯沙坦100mg/天，治疗8周。 可以看出，安博维降压效果显著优于氯沙坦。 * The principal finding of VALUE was that, for the primary composite endpoint of cardiac mortality and morbidity, there were no significant differences in these high-risk patients treated with valsartan- or amlodipine-based regimens.1 This was observed despite significant differences in achieved blood pressures. In a recent meta-regression analysis ba